Seres Therapeutics Inc., of Cambridge, Mass., said it closed its IPO of 8,545,138 shares of its common stock at $18 each, which includes the exercise in full by the underwriters of their option to purchase 1,114,583 additional shares of common stock. The net proceeds from the offering are estimated to be approximately $139.8 million.